Bio

Henrik Laursen is a partner in our Corporate Finance team and has extensive experience in large complex transactions across all public M&A and capital markets transactions (IPOs, rights issues, ABBs, takeovers, restructurings, etc.) as well venture capital and private M&A transactions. In addition to transactional work, Henrik provides advice in relation to ongoing disclosure obligations and corporate governance. Henrik is among the most active capital markets lawyers in Denmark, having completed transactions with an aggregate value of more than DKK 200bn. Henrik has been involved in several Danish landmark transactions across multiple industries, including the IPOs of Netcompany, Nets, ISS and Scandinavian Tobacco Group, the takeover bids on Topdanmark and Nørresundby Bank and led the Plesner equity capital markets (ECM) team advising Tryg on its DKK 37bn Rights Issue, the largest ever ECM transaction in Denmark. In addition, Henrik regularly advises most Danish and international investment banks active in Denmark. In addition to substantial experience and a successful track record with capital markets transactions in the Danish market, Henrik is among the most experienced Danish practitioners within cross-border capital markets transactions, currently advising Noble Corporation on its combination with Maersk Drilling and subsequent listing on NYSE and Nasdaq Copenhagen and have advised on the IPOs of Forward Pharma (first main listing on Nasdaq NYC), Ascendis Pharma (second main listing on Nasdaq NYC), Bavarian Nordic (abandoned US IPO), Zealand Pharma (first dual-listing on Nasdaq NYC), Orphazyme (third dual-listing on Nasdaq NYC) Nordic Waterproofing (IPO on Nasdaq Stockholm) as well as the restructuring of SEK 350m bonds issued by Trigon Agri A/S (listed on Nasdaq Stockholm). While working across multiple industries, Henrik has a particular focus on the technology and life science sectors as well as providing advice to financial institutions.